Innovacion y Desarrollo de Estrategias en Salud
12
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.3%
1 terminated/withdrawn out of 12 trials
87.5%
+1.0% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Safety and Efficacy of RAP-103 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects
Role: collaborator
Efficacy and Safety of L. Plantarum and P. Acidilactici in Children With Upper Respiratory Tract Infections
Role: collaborator
L. Reuteri DSM 17938 and L. Reuteri ATCC PTA 6475 in Moderate to Severe Irritable Bowel in Adults
Role: lead
Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19
Role: collaborator
Topical L. Reuteri in Children With Atopic Dermatitis
Role: lead
L. Reuteri ATCC PTA 5289 + L. Reuteri DSM 17938 in Pregnant Women
Role: lead
Clinical Trial of L. Reuteri in Infantile Colic 2017
Role: lead
Lactobacillus Reuteri DSM17938 in C-Section Infants
Role: lead
L. Reuteri ATCC PTA 5289 & L. Reuteri DSM 17938 for the Treatment of Children With Pharyngitis and/or Tonsillitis
Role: lead
Lactobacillus Reuteri for Treatment of Uncomplicated UTI in Pregnant Women
Role: lead
Montelukast and Loratadine in Children With Asthma
Role: lead
Clinical Trial of L. Reuteri in Urinary Tract Infections in Non Pregnant Women
Role: lead
All 12 trials loaded